4.7 Article

In Vitro Antimicrobial Susceptibility of Bacterial Enteropathogens Isolated from International Travelers to Mexico, Guatemala, and India from 2006 to 2008

Journal

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Volume 55, Issue 2, Pages 874-878

Publisher

AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.00739-10

Keywords

-

Ask authors/readers for more resources

The incidence rates of travelers' diarrhea (TD) have remained high for the last 50 years. More recently, there have been increasing recommendations for self-initiated therapy and use of prophylactic drugs for TD. We last examined the in vitro susceptibilities of commonly used antibiotics against TD pathogens in 1997. We now examine 456 enteropathogens isolated from adult travelers to Mexico, India, and Guatemala with diarrhea acquired between 2006 and 2008 to determine changes in susceptibility against 10 different antimicrobials by the agar dilution method. Traditional antibiotics, such as ampicillin, trimethoprim-sulfamethoxazole, and doxycycline, continue to show high levels of resistance. Current first-line antibiotic agents, including fluoroquinolones and azithromycin, showed significantly higher MICs than in our earlier study, and MIC90 levels were above the Clinical and Laboratory Standards Institute cutoffs for resistance. There were significant geographical differences in resistance patterns when Central America was compared with India. Entertoxigenic Escherichia coli (ETEC) isolates showed increased resistance to ciprofloxacin (P = 0.023) and levofloxacin (P = 0.0078) in India compared with Central America. Enteroaggregative E. coli (EAEC) isolates from Central America showed increased resistance to nearly all of the antibiotics tested. Compared to MICs of isolates 10 years prior, there were 4-to 10-fold increases in MIC90 values for ceftriaxone, ciprofloxacin, levofloxacin, and azithromycin for both ETEC and EAEC. There were no significant changes in rifaximin MICs. Rising MICs over time imply the need for continuous surveillance of susceptibility patterns worldwide and geographically specific recommendations in TD therapy.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Review Gastroenterology & Hepatology

Mechanism of action and therapeutic benefit of rifaximin in patients with irritable bowel syndrome: a narrative review

William D. Chey, Eric D. Shah, Herbert L. DuPont

THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2020)

Article Immunology

Renal Impairment, C. difficile Recurrence, and the Differential Effect of Bezlotoxumab: A Post Hoc Analysis of Pooled Data From 2 Randomized Clinical Trials

Yoav Golan, Herbert L. DuPont, Fernando Aldomiro, Erin H. Jensen, Mary E. Hanson, Mary Beth Dorr

OPEN FORUM INFECTIOUS DISEASES (2020)

Article Infectious Diseases

Nonmetabolizable Arabinose Inhibits Vibrio cholerae Growth in M9 Medium with Gluconate as the Sole Carbon Source

Taniya Golder, Asish Kumar Mukhopadhyay, Hemanta Koley, Ranjan Kumar Nandy

JAPANESE JOURNAL OF INFECTIOUS DISEASES (2020)

Review Immunology

Virulence Regulation and Innate Host Response in the Pathogenicity ofVibrio cholerae

Thandavarayan Ramamurthy, Ranjan K. Nandy, Asish K. Mukhopadhyay, Shanta Dutta, Ankur Mutreja, Keinosuke Okamoto, Shin-Ichi Miyoshi, G. Balakrish Nair, Amit Ghosh

FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY (2020)

Correction Immunology

Renal Impairment, C. difficile Recurrence, and the Differential Effect of Bezlotoxumab: A Post Hoc Analysis of Pooled Data From 2 Randomized Clinical Trials (vol 7, ofaa248, 2020)

Yoav Golan, Herbert L. DuPont, Fernando Aldomiro, Erin H. Jensen, Mary E. Hanson, Mary Beth Dorr

OPEN FORUM INFECTIOUS DISEASES (2021)

Article Immunology

Potential role of probiotics in reducing Clostridioides difficile virulence: Interference with quorum sensing systems

Sathursha Gunaratnam, Mathieu Millette, Lynne McFarland, Herbert L. DuPont, Monique Lacroix

Summary: This paper discusses the potential of opportunistic pathogenic bacteria to cause disease when disrupting the normal microbiome, and current therapeutic strategies for Clostridioides difficile, including disrupting virulence factor production through interfering with quorum sensing systems. Probiotics and other QS inhibitors targeting QS systems may represent important new directions for the treatment and prevention of C. difficile infections.

MICROBIAL PATHOGENESIS (2021)

Article Infectious Diseases

Effects of antibiotic resistance, drug target attainment, bacterial pathogenicity and virulence, and antibiotic access and affordability on outcomes in neonatal sepsis: an international microbiology and drug evaluation prospective substudy (BARNARDS)

Kathryn M. Thomson, Calie Dyer, Feiyan Liu, Kirsty Sands, Edward Portal, Maria J. Carvalho, Matthew Barrell, Ian Boostrom, Susanna Dunachie, Refath Farzana, Ana Ferreira, Francis Frayne, Brekhna Hassan, Ellis Jones, Lim Jones, Jordan Mathias, Rebecca Milton, Jessica Rees, Grace J. Chan, Delayehu Bekele, Abayneh Mahlet, Sulagna Basu, Ranjan K. Nandy, Bijan Saha, Kenneth Iregbu, Fatima Modibbo, Stella Uwaezuoke, Rabaab Zahra, Haider Shirazi, Najeeb U. Syed, Jean-Baptiste Mazarati, Aniceth Rucogoza, Lucie Gaju, Shaheen Mehtar, Andre N. H. Bulabula, Andrew Whitelaw, Johan G. C. van Hasselt, Timothy R. Walsh

Summary: When advocating antibiotic treatments, accessibility and affordability must be considered, tailored to the variance in economic health structures across low- and middle-income countries. Funding comes from The Bill & Melinda Gates Foundation. This article is published under an Open Access license.

LANCET INFECTIOUS DISEASES (2021)

Article Immunology

Emergence of Clinical Clostridioides difficile Isolates With Decreased Susceptibility to Vancomycin

Charles Darkoh, Kadiatou Keita, Chioma Odo, Micah Oyaro, Eric L. Brown, Cesar A. Arias, Blake M. Hanson, Herbert L. DuPont

Summary: A study found that vancomycin nonsusceptible strains of Clostridioides difficile are circulating in patient populations, posing a serious challenge to treatment as vancomycin is a first-line antibiotic for CDI. Routine susceptibility testing may be necessary.

CLINICAL INFECTIOUS DISEASES (2022)

Article Immunology

Challenges for Programmatic Implementation of Oral Cholera Vaccine in India

Debjit Chakraborty, Suman Kanungo, Ranjan Kumar Nandy, Alok Kumar Deb, Asish Kumar Mukhopadhyay, Shanta Dutta

Summary: Cholera remains a major issue in India, but faces challenges such as lack of a national control plan, inaccurate reporting, infrastructure and vaccine distribution issues.

JOURNAL OF INFECTIOUS DISEASES (2021)

Article Infectious Diseases

Durable reduction of Clostridioides difficile infection recurrence and microbiome restoration after treatment with RBX2660: results from an open-label phase 2 clinical trial

Robert Orenstein, Erik R. Dubberke, Sahil Khanna, Christine H. Lee, David Yoho, Stuart Johnson, Gail Hecht, Herbert L. DuPont, Dale N. Gerding, Ken F. Blount, Sarah Mische, Adam Harvey

Summary: In this Phase 2 trial, RBX2660 was found to be safe and effective in reducing the recurrence of rCDI compared to a historical control group. Microbiome changes in participants treated with RBX2660 were consistent with protective changes against C. difficile recurrence.

BMC INFECTIOUS DISEASES (2022)

Letter Immunology

Untitled Reply

Charles Darkoh, Herbert L. DuPont, Cesar A. Arias, Micah Oyaro, Eric L. Brown, Blake M. Hanson

CLINICAL INFECTIOUS DISEASES (2022)

Review Microbiology

Intestinal IgA-Coated Bacteria in Healthy- and Altered-Microbiomes (Dysbiosis) and Predictive Value in Successful Fecal Microbiota Transplantation

Herbert L. L. DuPont, Zhi-Dong Jiang, Ashley S. S. Alexander, Andrew W. W. DuPont, Eric L. L. Brown

Summary: IgA-coated bacteria in the gut provide important homeostatic functions and their impairment is associated with dysbiosis. Fecal microbiota transplantation has been successful in engrafting healthy microbiota and metabolites, with IgA-coated bacteria being transferred to recipients. The evaluation of the IgA-biome should be included in FMT studies, using metagenomic methods to better identify and compare microbiota data.

MICROORGANISMS (2023)

Article Neurosciences

IgA-Biome Profiles Correlate with Clinical Parkinson's Disease Subtypes

Eric L. Brown, Heather T. Essigmann, Kristi L. Hoffman, Ashley S. Alexander, Michael Newmark, Zhi-Dong Jiang, Jessika Suescun, Mya C. Schiess, Craig L. Hanis, Herbert L. DuPont

Summary: Parkinson's disease is a heterogeneous neurodegenerative disorder with distinct gut microbiome patterns. This study characterized the IgA-Biome of individuals with different clinical subtypes of Parkinson's disease and identified unique bacterial profiles associated with these subtypes.

JOURNAL OF PARKINSONS DISEASE (2023)

Article Public, Environmental & Occupational Health

Neonatal sepsis and mortality in low-income and middle-income countries from a facility-based birth cohort: an international multisite prospective observational study

Rebecca Milton, David Gillespie, Calie Dyer, Khadijeh Taiyari, Maria J. Carvalho, Kathryn Thomson, Kirsty Sands, Edward A. R. Portal, Kerenza Hood, Ana Ferreira, Thomas Hender, Nigel Kirby, Jordan Mathias, Maria Nieto, William J. Watkins, Delayehu Bekele, Mahlet Abayneh, Semaria Solomon, Sulagna Basu, Ranjan K. Nandy, Bijan Saha, Kenneth Iregbu, Fatima Z. Modibbo, Stella Uwaezuoke, Rabaab Zahra, Haider Shirazi, Syed U. Najeeb, Jean-Baptiste Mazarati, Aniceth Rucogoza, Lucie Gaju, Shaheen Mehtar, Andre N. H. Bulabula, Andrew C. Whitelaw, Timothy R. Walsh, Grace J. Chan

Summary: This study aimed to determine the incidence and associations with neonatal sepsis and all-cause mortality in facility-born neonates in low-income and middle-income countries (LMICs). Findings reveal a high incidence of neonatal sepsis and its significant impact on mortality rates in LMICs.

LANCET GLOBAL HEALTH (2022)

Article Oncology

Safety and efficacy of fecal microbiota transplantation to treat and prevent recurrent Clostridioides difficile in cancer patients

Hiba Ali, Shruti Khurana, Weijie Ma, Yuanzun Peng, Zhi-Dong Jiang, Herbert DuPont, Hao Chi Zhang, Anusha S. Thomas, Pablo Okhuysen, Yinghong Wang

Summary: Patients with cancer who underwent FMT for rCDI showed a high response rate and no serious adverse events or mortality within 30 days. However, additional antibiotic use for complications from chemotherapy or immunosuppression may negatively affect the efficacy of FMT in this population with advanced cancer.

JOURNAL OF CANCER (2021)

No Data Available